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Micro-RNAs (miRNAs) are a class of non-coding RNAs that
post-transcriptionally regulate gene expression via the RNA inter-
ferencepathway. In addition to roles innormaldevelopment,miR-
NAs have recently been implicated in a range of human diseases,
including cancer. We recently demonstrated that a polycistronic
cluster ofmiRNAs,miR-17–92, is oncogenic in amousemodel for
Burkitt’s lymphoma. This is due, in part, to a reduced apoptotic
program. In an effort to understand the regulation of miR-17–92,
wehave studied thepromoter structureof thismiRNAcluster.The
primary transcript initiates from a consensus initiator sequence
downstream of a nonconsensus TATA box. The core promoter
region contains two functional E2F transcription factor binding
sites. Chromatin immunoprecipitation demonstrates that E2F3 is
theprimaryE2F familymember thatoccupies thepromoter.These
data place miR-17–92 in a regulatory loop between E2F3 and the
miR-17targetE2F1.WeproposeamodelwherebymiR-17–92pro-
motes cell proliferation by shifting the E2F transcriptional balance
away from the pro-apoptotic E2F1 and toward the proliferative
E2F3 transcriptional network.
It is becoming clear that non-coding RNAs play an important
role in the regulation of cell function and can contribute to human
disease. One group of non-coding RNAs that has generatedmuch
recent attention is miRNAs.3 These small RNAs have widespread
impact ongene expression via theRNA interferencepathway.The
founding miRNA, lin-4, was discovered over 20 years ago in the
nematode Caenorhabditis elegans (1, 2). More recently a large
number of miRNA genes have been identified in a range of orga-
nisms. There are currently 474 human miRNAs listed in the
Sanger data base, andmanymore are predicted to exist (3).
miRNAbiogenesis begins with a primary transcript that is gen-
erated by RNA polymerase II (see Ref. 4 for a review). Sequential
processing events by the ribonuclease III enzymes Drosha and
Dicer yield the mature miRNA species. Averaging 22 nucleotides
long, thematuremiRNAis loaded into theRNA-inducedsilencing
complex where it directs translational suppression of target
mRNAs. Several computational algorithms have been developed
with the goal of defining the networks of genes regulated by miR-
NAs (see Ref. 5 for a review). While the exact list of targets is not
defined, the predicted targets extend to genes involved in amyriad
of cellularprocesses. It is estimated that30%of thehumangenome
is under miRNA post-transcriptional regulation.
Despite the large number of candidate targets, the exact cel-
lular pathways that are regulated by miRNAs are only begin-
ning to be understood, particularly in mammals. miRNAs have
been implicated in muscle development, hematopoietic differ-
entiation, insulin regulation, and cell proliferation and apopto-
sis (see Ref. 6 for a review).
We recently reported that a polycistronic cluster ofmiRNAs,
miR-17–92, can cooperate with c-Myc in a mouse model for
lymphomagenesis (7). This miRNA cluster has also been func-
tionally implicated in colorectal carcinoma and lung carcinoma
and has been defined as a commonmiRNA signature in several
solid tumors (8–10). Expression of miR-17–92 is high in pro-
liferating cells and is regulated in part by c-Myc itself (11). In an
effort to understand the transcriptional regulation of miR-
17–92 and its connection to cell proliferation we characterized
the promoter region of this miRNA cluster. Here we describe
the promoter organization of miR-17–92 and demonstrate its
direct regulation by E2F transcription factors.
EXPERIMENTAL PROCEDURES
Promoter Reporter Constructs—Promoter regions were
amplified from human genomic DNA using the following
primer sets: pro1353 5, TTTCAGATTTGGCCTTTTATTTT;
pro230 5, GGAGGTCGGAAGTACTTTGTTT; pro1353 3
and pro230 3, AGGAGAGCTTCGCGGAGGAG; thymidine
kinase-1 (TK-1) 5, AGGAACCTTGCTTGGGAAAC;TK-1 3,
ACGAACCCGAGTACTCTCCA. PCR products were cloned
into the promoterless vector pGL3 Basic (Promega) using
NheI/XhoI. Site directed mutagenesis was performed with the
QuikChange kit (Stratagene) using the pro230/pGL3 vector as
template and the following primer sets: E2F SITE SD1 5, CG-
ACCTGCGCCTTCGATCCACTTCGCGCCCTC; E2F SITE
SD1 3, GAGGGCGCGAAGTGGATCGAAGGCGCAGG-
TCG; E2F SITE SD25, CTTCGCGCCACTTCGATCCCTCG-
GGCGTCCGG; E2F SITE SD23, CCGGACGCCCGAGGGA-
TCGAAGTGGCGCGAAG; TATA SD 5, GGGCTTGTCCG-
GAATTCCGTTGAGGCGG; TATA SD 3, CCGCCTCAA-
CGGAATTCCGGACAAGCCC.
Promoter activity was determined by co-transfection of the
pGL3 promoter reporter (400 ng/well) with pRLSV40 (Renilla
luciferase, Promega)(100 ng/well) into HEK-293 cells using
FuGENE 6 (Roche Applied Science) and measurement of lucif-
erase activity with the dual luciferase kit (Promega). Assays
were performed in triplicate and standard deviations calculated.
Activitywas defined as Firefly/Renilla ratio, normalized to control
vector transfection. For E2F transactivation assays, promoter
activity was measured similarly with the following exceptions:
NIH-3T3were transfectedwith the pGL3 promoter reporter (400
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ng/well) and pRLSV40 (200 ng/well), with or without E2F expres-
sion plasmids (400 ng/well), using Lipofectamine 2000 (Invitro-
gen). Activity was defined as Firefly/Renilla ratio normalized to
activity in the absence of transfected E2F1.
5-RACE Mapping of Transcript—HEK-293 cells were tran-
siently transfected with the pro1353 vector and total RNA pre-
pared (TRIzol, Invitrogen). RNA was decapped with tobacco
acid phosphatase (Epicenter) and ligated to the synthetic RNA
CGGUUUAAACGGUCCUUUAAA. cDNA was prepared
(Superscript) and PCR performed using the following primers:
RACE 5, CGGTTTAAACGGTCCTTTAAA and RACE 3,
GTTCCATCTTCCAGCGGATA. PCR products were cloned
into TOPO TA vector pCR2.1 and sequenced.
Chromatin Immunoprecipitation—HEK-293 cells (1  10-cm
plate/immunoprecipitation) were cross-linked/fixed in 1% form-
aldehyde for 10 min at room temperature. Cells were washed in
PBS and the cross-linking halted with 125 mM glycine treatment
for 5 min at room temperature. Cells were extracted in 300 l of
SolA for 10 min on ice. Nuclei were recovered by centrifugation
and extracted with 300 l of SolB for 20min on ice and sonicated
5 times for 10 s each. Nuclear lysates were centrifuged, and the
supernatant was diluted in 1 volume of buffer B and precleared
with 60 l of protein-A-Sepharose plus 2 g of sheared salmon
sperm DNA. Chromatin was captured with primary antibody at
the following amounts: BD E2F1, 9 g (BD #554213); SC E2F1, 3
g (SC-193); SC E2F2, 6 g (SC-633); SC E2F3, 3 g (SC-878);
glyceraldehyde-3-phosphate dehydrogenase, 2 g (Chemicon
MAB374).Afterovernightcapture thechromatinwasprecipitated
with 20 l of protein-A-Sepharose, washed sequentially in TSE1,
TSE2,TSE3, andTE.Chromatinwas elutedwith250l of buffer E
for 15 min at room temperature. Eluate was adjusted with 4 l of
500 mM EDTA, 9 l of 1.0 M Tris, pH 7.6, 2 l of 10 mg/ml pro-
teinaseK, and2l of 10mg/mlRNaseAand incubatedat 45 °C for
1 h. Chromatin was decrosslinked at 65 °C overnight. DNA was
recovered by phenol extraction and amplified with the following
primer sets: TK1 5, ATGCCTGGACACAGGCTATC; TK1 3,
CAAATCTCCCGCCAGGTC; POLA5, CCAAATCTTTTCC-
CATCAGC; POLA3, CTCGCCCCTATCTCACAGTC; 1792p1
5, GAAGAAGGAGGTGCTCCTGA; 1792p1 3, GCCCAGCT-
GCATTTAGTAAGA; 1792p2 5, ACCAGCTAGCGGAGGTC-
GGAAGTACTTTGTTT; 1792p2 3, ACCATCGAGAGGAGA-
GCTTCGCGGAGGAG; 1792p3 5, ATTCACCCACATGGTC-
CTTC; 1792p3 3, GCCTGCGCTTTACTACGAC.
Buffers—The following buffers were used: SolA, 10 mMHepes,
pH 7.9, 0.5% Nonidet P-40, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM
dithiothreitol, protease inhibitors; SolB, 20mMHepes, pH7.9, 25%
glycerol, 0.5% Nonidet P-40, 0.42 M NaCl, 1.5 mMMgCl2, 0.2 mM
EDTA, protease inhibitors; Buffer B, 1% Triton X-100, 2 mM
EDTA, 50mMNaCl, 20mMTris-HCl, pH 7.9, protease inhibitors;
TSE1, 0.1% SDS, 1%TritonX-100, 2mMEDTA, 150mMNaCl, 20
mM Tris-Cl, pH 8.1; TSE2, 0.1% SDS, 1% Triton X-100, 2 mM
EDTA,500mMNaCl,20mMTris-Cl,pH8.1;TSE3,0.25MLiCl, 1%
Nonidet P-40, 1% deoxycholate, 1 mM EDTA, 10 mM Tris-Cl, pH
8.1; Buffer E, 1% SDS, 0.1 MNaHCO3.
RESULTS AND DISCUSSION
The miR-17–92 cluster is comprised of miR-17, miR-18a,
miR-19a, miR-20a, miR-19b-1, and miR-92–1, all of which are
housed in the expressed sequence tag (EST) chr13orf25 (see
Fig. 1A). The sequence upstream of the putative transcriptional
start site is highly conserved across vertebrate genomes and
contains an extensive CpG island, indicative of a core promoter
region. In an effort to identify the true transcriptional start site
we employed RACE cloning of the 5 end. This was unsuccess-
ful due to the extreme GC content of the 5 end of the RNA. As
an alternative strategy we cloned a 1353-nucleotide genomic
region upstream of the chr13orf25 transcript, overlapping the
5 end of the EST (construct pro1353, Fig. 1A). This region
conferred strong transcriptional activity to a promoterless
luciferase reporter vector (Fig. 1B). A smaller promoter region
that contained the minimal conserved region had less activity,
presumably due to removal of positive cis-elements (construct
pro230, Fig. 1, A and B). RACE cloning of the pro1353/lucifer-
ase fusionwas successful, enabling us tomap the preferred start
site 134 nucleotides upstream of the 5 end of the EST (Fig. 1A).
We believe this is the true start site, since it resides within a
highly conserved region, in contrast to the terminus of the EST,
which is non-conserved. The identified start site conforms to
the initiator consensus sequence YYANTY, where the adenine
is the start of transcription. In addition, there is a nonconsensus
TATA box 32 from the start site, which is within the pre-
ferred location (29 to 32, measured from the first thymine)
(12, 13). The TATA box matches the sequence of the SV-40
early gene TATA box, which does not bind TBP but is still
important for transcriptional activity at the downstream start
site (14, 15). Similarly, the miR-17–92 TATA box is important
for transcription, as site-directed mutation of the sequence
attenuates transcriptional activity (Fig. 1B).
Expression of miR-17–92 has been correlated with prolifer-
ating cells. Therefore, we hypothesized that its promoter would
contain binding sites for transcription factors with established
roles in cell proliferation. Analysis of the promoter revealed two
conserved E2F binding sites downstream of the start site (Fig.
1A). We tested the function of these sites by cotransfection of
the pro230 and pro1353 promoter reporter constructs with an
expression plasmid that directs expression of human E2F1.
Both reporters were strongly transactivated by E2F1 (Fig. 2A).
Shown for comparison is a reporter for TK-1, a promoter
known to be E2F regulated. The E2F1 point mutant L132E,
which lacks DNA binding activity, had a minimal effect on the
reporter. E2F1 transactivatesmany genes, including other tran-
scription factors such as c-Myc. To confirm that E2F-mediated
regulation of miR-17–92 is direct we mutated the E2F binding
sites from the pro230 reporter by site-directed mutagenesis
(Fig. 2B). Removal of either site essentially abolished transacti-
vation by E2F1 (Fig. 2C).
Nine E2F family members have been described: E2F1, E2F2,
and E2F3a, which are transcriptional activators, and E2F3b to
E2F8, which are transcriptional repressors (see Ref. 16 for a
review). The essential role of E2Fs in the progression of the cell
cycle is well known. A large number of S phase genes, including
thymidine kinase, DNA polymerase , and Cyclins E and A, are
transactivated by E2Fs. Loss of all three activating E2Fs leads to
a failure of S phase entry (17). Loss of a single activating E2F
does not lead to cell cycle defects due to partial redundancy;
however, there are specialized roles for individual family mem-
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bers (18). In particular, E2Fs promote apoptosis in some cellu-
lar contexts, and this is dependent on E2F1 activity. Mice lack-
ing E2F1 are tumor prone as a consequence, while mice lacking
E2F3 are not (19–21). Similarly, mouse embryo fibroblasts that
are deficient for E2F1 are resistant to apoptosis, even in the
presence of elevated E2F3 (22).
While our data implicates E2F1 in the regulation ofmiR-17–92,
it is probable that isoform specificity is lost as a consequence of
overexpression. To identify the endogenous family member that
occupies the miR-17–92 promoter we employed chromatin
immunoprecipitation (Fig. 3). As controls we analyzed the DNA
polymerase alphapromoter,which is occupiedby all three activat-
ing E2Fs, and TK-1, which is occupied predominantly by E2F3
(23). Three independent primer sets flanking themiR-17–92 start
site were used to detect E2F occupancy. All three primer sets
detected E2F3 as the isoform predominantly associated with the
promoter region.While this data does not rule out E2F1 and E2F2
associationwithother regionsof thepromoter, it confirms the role
of E2F3 in the regulation of miR-17–92.
These data allow us to develop a model for miR-17–92 func-
tion (Fig. 4). Proliferative signals that converge on the Retino-
blastoma gene product lead to activity of E2F transcription fac-
tors (24). In addition to induction of genes essential for S phase
entry, E2Fs transactivate the oncogenic miRNAs miR-17–92.
The exact cellular role of miR-17–92 is unknown, but lympho-
mas that express these miRNAs at a high level have reduced
apoptosis (7). E2F1 is a validated target of miR-17 and miR-20
(11). Therefore, elevation of miR-17–92 would lead to
decreased E2F1 protein and would thus attenuate E2F induced
apoptosis. Since E2F3 is the predominant isoform that regu-
lates miR-17–92 in cells, the targeting of E2F1 would not pro-
duce negative feedback but would rather promote E2F3 prolif-
erative signal rather than E2F1 apoptotic signal.
FIGURE 1. Organization of the miR-17–92 gene. A, the gene structure of the primary transcript for miR-17–92 is shown. The positions of the mature miRNAs
in the polycistronic cluster are shown by boxes. Vertebrate sequence conservation is indicated in the plot. The origin of the promoter reporter constructs,
pro1343 and pro230, are shown. Both contain the same 3 end, which is 10 nucleotides downstream of the 5 terminus of the chr13orf25 EST. The expanded
region indicates salient features around the start site. B, transcriptional activity of reporter constructs in HEK-293 cells, as measured by Firefly/Renilla luciferase
activity. The pro230 TATA SD construct has the following TATA box mutation: TATTTA to GAATTC. pGL3 basic is the parental promoterless reporter vector.
FIGURE 2. Regulation of miR-17–92 by E2F. A, the reporter constructs
pro1353 (left panel), pro230 (center panel), and TK-1 (right panel) were co-
transfected with a control vector, a vector directing expression of human
E2F1, or a vector directing expression of the DNA binding domain mutant
allele of E2F1 L132E, into NIH-3T3 cells. Firefly/Renilla luciferase ratios were
used to calculate fold induction. Cont., control. B, the sequence of the dual E2F
sites are shown in gray. Site-directed mutants are indicated. C, fold induction
of pro230 site-directed mutant reporters by wild type (WT) E2F1 is shown.
FIGURE 3. The miR-17–92 promoter is occupied by E2F3. A, the locations of
chromatin immunoprecipitation primer sets are shown. The transcriptional start
site and E2F sites are indicated. B, HEK-293 chromatin was immunoprecipitated
with the indicated antibodies and associated DNA was detected by the indicated
primer sets. Two different E2F1 antibodies were used, as indicated in the experi-
mental section. Note: the P1 primer set is upstream of the indicated E2F sites but
is near another predicted, but uncharacterized, E2F site. nt, nucleotides.
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Our data also provide a mechanism for elevated miR-17–92
in proliferating cells. E2F activity is periodic with the cell cycle,
reaching a peak during S phase (for E2F1–3) (24). We do not
expect miR-17–92 to follow this periodicity, since the half-life
of mature miRNAs is much longer than the typical cell cycle.4
Rather, cycling cells would have elevated steady state levels of
miR-17–92 due to the periodic burst of E2F activity during S
phase, while quiescent cells would have reduced miR-17–92
levels. In a parallel pathway, miR-17–92 is regulated by c-Myc
(11). E2F and Myc transactivate each other, providing a com-
plex regulatory signal for miR-17–92 expression.
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